Evidence map›Paper›PMID 27349564›Full record

ArticleInternational urology and nephrology2016

Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume.

Peter K F Chiu, Monique J Roobol, Jeremy Y Teoh, Wai-Man Lee, Siu-Ying Yip, See-Ming Hou, Chris H Bangma, Chi-Fai Ng

5 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03891732 active not recruitingnot on this mapstarted 2019, after this paper: background citation

The Use of MRI Prostate in Improving Detection of Significant Prostate Cancer in a Screening Population of Chinese Men With Elevated PSA

TypeobservationalSponsorChinese University of Hong KongRan2019 to 2024Enrolled690ConditionsProstate Cancer, PSA, MRIArmsMRI prostate
NCT05438524 completednot on this mapstarted 2021, after this paper: background citation

The Performance of MRI Prostate in Men With Different Prostate Health Index (Phi) Values: Can we Save Some MRI Scans?

TypeobservationalSponsorChinese University of Hong KongRan2021 to 2024Enrolled159ConditionsProstate Cancer
NCT05443412 recruitingnot on this mapstarted 2023, after this paper: background citation

Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer Detection: A Synergy of Novel Biomarkers, Advanced Imaging, and Robotic-assisted Diagnosis

TypeobservationalSponsorChinese University of Hong KongRan2023 to 2026Enrolled510ConditionsProstate CancerArmsDiagnostic test for prostate cancer
NCT06303622 narecruitingnot on this mapstarted 2025, after this paper: background citation

A Randomised Controlled Trial Comparing MRI-Ultrasound Fusion and Cognitive-guided Biopsy for the Detection of Clinically Significant Prostate Cancer: the PROFUSION Trial

TypeinterventionalSponsorChinese University of Hong KongRan2025 to 2027Enrolled1,250ConditionsProstate CancerArmsMRI-USG fusion approach, Cognitive-guided approach
NCT07386496 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

The Role of 18F-PSMA PET in Prostate Cancer Diagnosis in Equivocal MRI: a Multi-center Randomised Controlled Trial

TypeinterventionalSponsorChinese University of Hong KongRan2026 to 2028Enrolled250ConditionsProstate CancerArmsMRI+PSMA-guided approach, MRI-guided approach
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. New benzothieno[2,3-Journal of enzyme inhibition and medicinal chemistry · 2021
    Article
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Review
  13. Review
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Peter K F ChiuDivision of Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Monique J RoobolDepartment of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Jeremy Y TeohDivision of Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Wai-Man LeeDivision of Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Siu-Ying YipDivision of Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
See-Ming HouDivision of Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Chris H BangmaDepartment of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Chi-Fai NgDivision of Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China. ngcf@surgery.cuhk.edu.hk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate PSA- and PHI (prostate health index)-based models for prediction of prostate cancer (PCa) and the feasibility of using DRE-estimated prostate volume (DRE-PV) in the models.

methodsThis study included 569 Chinese men with PSA 4-10 ng/mL and non-suspicious DRE with transrectal ultrasound (TRUS) 10-core prostate biopsies performed between April 2008 and July 2015. DRE-PV was estimated using 3 pre-defined classes: 25, 40, or 60 ml. The performance of PSA-based and PHI-based predictive models including age, DRE-PV, and TRUS prostate volume (TRUS-PV) was analyzed using logistic regression and area under the receiver operating curves (AUC), in both the whole cohort and the screening age group of 55-75.

resultsPCa and high-grade PCa (HGPCa) was diagnosed in 10.9 % (62/569) and 2.8 % (16/569) men, respectively. The performance of DRE-PV-based models was similar to TRUS-PV-based models. In the age group 55-75, the AUCs for PCa of PSA alone, PSA with DRE-PV and age, PHI alone, PHI with DRE-PV and age, and PHI with TRUS-PV and age were 0.54, 0.71, 0.76, 0.78, and 0.78, respectively. The corresponding AUCs for HGPCa were higher (0.60, 0.70, 0.85, 0.83, and 0.83). At 10 and 20 % risk threshold for PCa, 38.4 and 55.4 % biopsies could be avoided in the PHI-based model, respectively.

conclusionsPHI had better performance over PSA-based models and could reduce unnecessary biopsies. A DRE-assessed PV can replace TRUS-assessed PV in multivariate prediction models to facilitate clinical use.

Indexed as

AgedChinaDigital Rectal ExaminationFeasibility StudiesHealth Status IndicatorsHumansMaleMiddle AgedOrgan SizeProstateProstate-Specific AntigenProstatic NeoplasmsRisk AssessmentROC CurveProstate-Specific AntigenProstate cancerProstate health indexProstate-specific antigenProstate volumeRectal examinationRisk calculator

Identifiers

PMID27349564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.